. 2023 Oct 13;13(1):157. doi: 10.1038/s41408-023-00930-7

Table 3.

Summary of variables, distributions of patients according to four risk group models, and 3/5-year overall survival in original models and models from the current study.

Model (N of patients)	Original study					Current study N = 5126
	Model variables (points)	Risk groups (points)	% of patients	OS-years	OS (%)	N of patients (%)	3-year OS (%)	5-year OS (%)
IPI [3] N = 2031	Age >60 years (1) ECOG PS >1 (1) Stage III/IV (1) EN sites >1 (1) LDH >ULN (1)	L (0–1) LI (2) HI (3) H (4–5)	35 27 22 16	5-	73.0 51.0 43.0 26.0	1342 (26.2) 1267 (24.7) 1426 (27.8) 1091 (21.3)	92.3 80.2 69.6 49.1	85.8 74.7 62.2 43.6
aaIPI [3] >60 years N = 761	Stage III/IV (1) EN sites >1 (1) LDH >ULN (1)	L (0) LI (1) HI (2) H (3)	18 31 35 16	5-	56 44 37 21	1016 (19.8) 1277 (24.9) 1837 (35.8) 996 (19.4)	89.1 80.3 69.4 58.1	81.4 73.8 63.6 52.1
NCCN-IPI [8] N = 1650	Age ≤40 (0), 41–60 (1), 61–75 (2), >75 (3) ECOG PS >1 (1) Stage III/IV (1) EN sites ≥1 (1) LDH >1-3xULN (1), >3xULN (2)	L (0–1) LI (2) HI (3) H (4–5)	19.0 42.0 31.0 8.0	5-	96.0 82.0 64.0 33.0	414 (8.1) 1870 (36.5) 2129 (41.5) 713 (13.9)	99.2 87.6 67.8 40.9	97.1 81.8 60.1 33.4
DLBCL-PI [12] N = 1803	Age >70 (1) ECOG PS >1 (1) Stage III/IV (1) LDH >ULN (1) Albumin ≤40 g/L	L (0–1) LI (2) HI (3) H (4–5)	33.1 26.1 23.1 17.7	5-	87.0 69.0 53.0 37.0	1206 (23.5) 1283 (25.0) 1474 (28.8) 1163 (22,7)	93.5 83.7 70.9 46.1	89.5 76.0 64.1 38.5
aaDLBCL-PI^a [12] (≤70 years) N = 1169	ECOG PS >1 (1) EN sites >1 LDH >ULN (1) Albumin ≤40 g/L (1)	L (0) LI (1) HI (2) H (3-4)	27.2 30.8 25.3 16.7	5-	92.0 84.0 74.0 47.0	776 (15.1) 1499 (29.2) 1592 (31.1) 1259 (24.6)	91.2 85.3 71.1 52.8	85.5 77.9 64.5 47.4
Modified NCCN-IPI [30] N = 403	Age ≤40 (0), 41-60 (1), 61-75 (2), >75 (3) ECOG PS >1 (1) Stage III/IV (1) EN sites ≥1 (1) LDH > 1–3xULN (1), >3xULN (2) Albumin <35 g/L (1)	L (0-2) LI (3) HI (4-7) H (8-10)	24.0 19.0 49.0 8.0	5-	93.5 78.0 55.7 36.8	1049 (20.5) 935 (18.2) 2698 (52.6) 444 (8.7)	96.4 85.1 67.0 37.9	92.8 79.2 59.2 31.7
KPI [31] N = 323	ECOG PS >1 (1) EN sites ≥1 LDH >1–3xULN (1), >3xULN (2) Albumin <35 g/L (1)	L (0) LI (1-2)HI (3) H (4-5)	32.6 42.7 11.1 13.6	3-	96.4 84.7 63.8 33.3	1255 (24.5) 2737 (53.4) 702 (13.7) 432 (8.4)	89.4 76.2 55.1 43.7	82.3 69.9 47.9 40.3
Modified 3-factor Model [29] N = 274	ECOG PS >1 (1) Stage III/IV (1) ALC <1.0 x 10⁹/L (1)	Score 0 Score 1 Score 2 Score 3	32.0 34.0 25.0 9.0	3-	95.0 79.0 40.0 18.0	1249 (24.4) 2058 (40.1) 1435 (28.0) 384 (7.5)	90.2 76.8 63.0 44.9	84.5 69.7 56.8 39.4

Model (N of patients)

Original study

Current study
N = 5126

Model variables (points)

Risk groups (points)

% of patients

OS-years

OS (%)

N of patients (%)

3-year OS (%)

5-year OS (%)

IPI [3]

N = 2031

Age >60 years (1)

ECOG PS >1 (1)

Stage III/IV (1)

EN sites >1 (1)

LDH >ULN (1)

L (0–1)

LI (2)

HI (3)

H (4–5)

73.0

51.0

43.0

26.0

1342 (26.2)

1267 (24.7)

1426 (27.8)

1091 (21.3)

92.3

80.2

69.6

49.1

85.8

74.7

62.2

43.6

aaIPI [3]

>60 years

N = 761

Stage III/IV (1)

EN sites >1 (1)

LDH >ULN (1)

L (0)

LI (1)

HI (2)

H (3)

1016 (19.8)

1277 (24.9)

1837 (35.8)

996 (19.4)

89.1

80.3

69.4

58.1

81.4

73.8

63.6

52.1

NCCN-IPI [8]

N = 1650

Age ≤40 (0), 41–60 (1), 61–75 (2), >75 (3)

ECOG PS >1 (1)

Stage III/IV (1)

EN sites ≥1 (1)

LDH >1-3xULN (1), >3xULN (2)

L (0–1)

LI (2)

HI (3)

H (4–5)

19.0

42.0

31.0

8.0

96.0

82.0

64.0

33.0

414 (8.1)

1870 (36.5)

2129 (41.5)

713 (13.9)

99.2

87.6

67.8

40.9

97.1

81.8

60.1

33.4

DLBCL-PI [12]

N = 1803

Age >70 (1)

ECOG PS >1 (1)

Stage III/IV (1)

LDH >ULN (1)

Albumin ≤40 g/L

L (0–1)

LI (2)

HI (3)

H (4–5)

33.1

26.1

23.1

17.7

87.0

69.0

53.0

37.0

1206 (23.5)

1283 (25.0)

1474 (28.8)

1163 (22,7)

93.5

83.7

70.9

46.1

89.5

76.0

64.1

38.5

aaDLBCL-PI^a [12]

(≤70 years)

N = 1169

ECOG PS >1 (1)

EN sites >1

LDH >ULN (1)

Albumin ≤40 g/L (1)

L (0)

LI (1) HI (2)

H (3-4)

27.2

30.8

25.3

16.7

92.0

84.0

74.0

47.0

776 (15.1)

1499 (29.2)

1592 (31.1)

1259 (24.6)

91.2

85.3

71.1

52.8

85.5

77.9

64.5

47.4

Modified NCCN-IPI [30]

N = 403

Age ≤40 (0), 41-60 (1), 61-75 (2), >75 (3)

ECOG PS >1 (1)

Stage III/IV (1)

EN sites ≥1 (1)

LDH > 1–3xULN (1), >3xULN (2)

Albumin <35 g/L (1)

L (0-2)

LI (3)

HI (4-7)

H (8-10)

24.0

19.0

49.0

8.0

93.5

78.0

55.7

36.8

1049 (20.5)

935 (18.2)

2698 (52.6)

444 (8.7)

96.4

85.1

67.0

37.9

92.8

79.2

59.2

31.7

KPI [31]

N = 323

ECOG PS >1 (1)

EN sites ≥1

LDH >1–3xULN (1), >3xULN (2)

Albumin <35 g/L (1)

L (0)

LI (1-2)HI (3)

H (4-5)

32.6

42.7

11.1

13.6

96.4

84.7

63.8

33.3

1255 (24.5)

2737 (53.4)

702 (13.7)

432 (8.4)

89.4

76.2

55.1

43.7

82.3

69.9

47.9

40.3

Modified 3-factor Model [29]

N = 274

ECOG PS >1 (1)

Stage III/IV (1)

ALC <1.0 x 10⁹/L (1)

Score 0

Score 1

Score 2

Score 3

32.0

34.0

25.0

9.0

95.0

79.0

40.0

18.0

1249 (24.4)

2058 (40.1)

1435 (28.0)

384 (7.5)

90.2

76.8

63.0

44.9

84.5

69.7

56.8

39.4

aaDLBCL-PI age-adjusted DLBCL-PI, aaIPI age-adjusted IPI, ALC absolute lymphocyte count, DLBCL diffuse large B-cell lymphoma, DLBCL-PI DLBCL Prognostic Index, ECOG PS Eastern Oncology Cooperative Group performance status, EN extranodal, IPI International Prognostic Index, KPI Kyoto Prognostic Index, LDH lactate dehydrogenase, NCCN-IPI National Comprehensive Cancer Network-IPI, N number, OS overall survival, R-IPI Revised International Prognostic Index, ULN upper limit of normal.

^aDeveloped for younger patients; look in the original publication.